Objective: Obesity is driven by modifiable lifestyle factors whose effects may be mediated by epigenetics. Therefore, we investigated lifestyle effects on blood DNA methylation in participants of the LIFE-Adult study, a well-characterised population-based cohort from Germany. Research design and methods: Lifestyle scores (LS) based on diet, physical activity, smoking and alcohol intake were calculated in 4107 participants of the LIFE-Adult study. Fifty subjects with an extremely healthy lifestyle and 50 with an extremely unhealthy lifestyle (5th and 95th percentiles LS) were selected for genome-wide DNA methylation analysis in blood samples employing Illumina Infinium⃝R Methylation EPIC BeadChip system technology. Results: Differences in DNA methylation patterns between body mass index groups (<25 vs. >30 kg/m2) were rather marginal compared to inter-lifestyle dif- ferences (0 vs. 145 differentially methylated positions [DMPs]), which identified 4682 differentially methylated regions (DMRs; false discovery rate [FDR <5%) annotated to 4426 unique genes. A DMR annotated to the glutamine-fructose-6- phosphate transaminase 2 (GFPT2) locus showed the strongest hypomethylation (∼6.9%), and one annotated to glutamate rich 1 (ERICH1) showed the strongest hypermethylation (∼5.4%) in healthy compared to unhealthy lifestyle individu- als. Intersection analysis showed that diet, physical activity, smoking and alcohol intake equally contributed to the observed differences, which affected, among others, pathways related to glutamatergic synapses (adj. p < .01) and axon guid- ance (adj. p < .05). We showed that methylation age correlates with chronological age and waist-to-hip ratio with lower DNA methylation age (DNAmAge) acceler- ation distances in participants with healthy lifestyles. Finally, two identified top DMPs for the alanyl aminopeptidase (ANPEP) locus also showed the strongest expression quantitative trait methylation in blood. Conclusions: DNA methylation patterns help discriminate individuals with a healthy versus unhealthy lifestyle, which may mask subtle methylation differ- ences derived from obesity.

Cancer immunotherapy has gained attention in recent years for its successes in potentiating immune responses that can elicit tumor control. In particular, adoptive cell therapy (ACT), which involves the autologous/allogeneic transplant of ex vivo-cultivated tumor-specific T lymphocytes, can mediate potent tumor recognition and killing; however, durable clinical responses are often difficult to obtain in solid tumors. Solid tumors and their unique microenvironments have the capacity to evade and suppress antitumor immune responses and represent significant hurdles for effective ACT. Recently, we have discovered that chemical inhibition of histone deacetylases via MS-275 (Entinostat) during ACT can subvert tumor resistance to foster potent, broad-spectrum antitumor immunity. Overall, the work described supports the efficacy of ACT in the treatment of immunosuppressive, solid tumors; however, consistency in durable clinical outcomes can only be achieved through the concurrent therapeutic targeting of tumor resistance mechanisms. This thesis uses pre-clinical models to describe how tumor resistance to ACT can manifest, and demonstrates that concurrent MS-275 delivery drives extensive immunomodulation to promote sustained tumor clearance. This includes: 1) The polarization of tumor-infiltrating myeloid cells into cytotoxic effectors with the ability to reject immune escape variants 2) The inflammatory remodeling of the tumor microenvironment to potentiate epitope spreading against secondary tumor antigens 3) The transcriptional reprogramming of adoptively transferred T cells to overcome tumor-burden-dependent exhaustion We expect that the results will help facilitate the development of next-generation ACT platforms that will feature strategies for multi-mechanistic perturbation of tumor resistance. / Thesis / Doctor of Philosophy (PhD) / The host immune system has the ability to recognize and destroy tumor cells. Therapeutic platforms that leverage antitumor immune cells, specifically T cells, have shown potency in the elimination of cancer. In the clinic, cancer immunotherapies have demonstrated early success against hematological malignancies; however, are unreliable in the treatment of solid tumors. Solid tumors utilize intrinsic and adapted mechanisms of resistance to mitigate the effectiveness of cancer immunotherapy. This thesis pursues research questions aimed at understanding how tumors resist immunotherapy, what mechanisms are utilized, and how to overcome these obstacles. We anticipate that these results will contribute to the development and incorporation of strategies to subvert tumor resistance and potentiate T cells against solid tumors.

No description available.

No description available.

Although human liver tumor cells have reduced metabolic functions as compared to primary human hepatocytes (PHH) they are widely used for pre-screening tests of drug metabolism and toxicity. The aim of the present study was to modify liver cancer cell lines in order to improve their drug-metabolizing activities towards PHH. It is well-known that epigenetics is strongly modified in tumor cells and that epigenetic regulators influence the expression and function of Cytochrome P450 (CYP) enzymes through altering crucial transcription factors responsible for drug-metabolizing enzymes. Therefore, we screened the epigenetic status of four different liver cancer cell lines (Huh7, HLE, HepG2 and AKN-1) which were reported to have metabolizing drug activities. Our results showed that HepG2 cells demonstrated the highest similarity compared to PHH. Thus, we modified the epigenetic status of HepG2 cells towards ‘normal’ liver cells by 5-Azacytidine (5-AZA) and Vitamin C exposure. Then, mRNA expression of Epithelial-mesenchymal transition (EMT) marker SNAIL and CYP enzymes were measured by PCR and determinate specific drug metabolites, associated with CYP enzymes by LC/MS. Our results demonstrated an epigenetic shift in HepG2 cells towards PHH after exposure to 5-AZA and Vitamin C which resulted in a higher expression and activity of specific drug metabolizing CYP enzymes. Finally, we observed that 5-AZA and Vitamin C led to an increased expression of Hepatocyte nuclear factor 4α (HNF4α) and E-Cadherin and a significant down regulation of Snail1 (SNAIL), the key transcriptional repressor of E-Cadherin. Our study shows, that certain phase I genes and their enzyme activities are increased by epigenetic modification in HepG2 cells with a concomitant reduction of EMT marker gene SNAIL. The enhancing of liver specific functions in hepatoma cells using epigenetic modifiers opens new opportunities for the usage of cell lines as a potential liver in vitro model for drug testing and development.

<p>Valproic acid (VPA) is clinically utilized as an anti-convulsant and mood stabilizer, though its mechanism of action has not been fully elucidated.<strong> </strong>Evidence suggests an interaction between VPA and the melatonergic system as VPA up-regulated the melatonin MT₁ receptor subtype in rat C6 glioma cells. To determine if the observed effects can translate to an <em>in vivo </em>model, we investigated the effects of chronic VPA administration in a rat model on the expression of MT₁ and MT₂ receptors in the hippocampus. We also investigated the effect of chronic VPA treatment on the expression of the neurotrophic factors BDNF and GDNF in the rat hippocampus and striatum.</p> <p>(1) Animals were separated into two groups with the experimental group receiving VPA (4 mg/mL) for 17 days, and the control receiving vehicle. The hippocampus was dissected and MT₁, MT₂, BDNF and GDNF mRNA were analyzed with RT-PCR. (2) Animals were separated into three groups with the first group receiving VPA (4 mg/mL), the second receiving VPA (3 mg/mL) for 16 days, and the control receiving vehicle. MT₂ mRNA in the hippocampal subregions were analyzed with in situ hybridization.</p> <p>VPA induced the expression of MT₁ and MT₂ mRNA in the hippocampus in the experimental group compared to the control group. VPA also increased MT₂ mRNA expression in the subregions of the hippocampus. Additionally, BDNF and GDNF mRNA expression were increased in the VPA treatment group.</p> <p>These findings raise the interesting question of whether the diverse clinical effects of VPA involve an interaction with the melatonergic system.</p> / Master of Science (MSc)

Master of Science / Department of Anatomy and Physiology / Mark L. Weiss / When mouse embryonic stem cells (ESCs) were grown on mitotically inactivated rat umbilical cord-derived stromal cells (RUCs) in the absence of leukemia inhibitory factor (LIF) and 2-mercaptoethanol (2-MCE), the ESCs showed alkaline phosphatase (AP) staining. ESCs cultured on RUCs maintain expression of the following pluripotency genes, Nanog, Sox2 and Oct4 and grow at a slower rate when compared with ESCs grown on mitotically inactivated mouse embryonic fibroblasts (MEFs). Differences in gene expression for the markers of pluripotency Oct4, Sox2 and Nanog, AP staining and ESC growth rate were also observed after LIF and 2-MCE were removed from the co-cultures. Reverse transcriptase polymerase chain reaction (RT-PCR) suggested differences in Sox2 and Nanog mRNA expression, with both genes being expressed at higher levels in the ESCs cultured on RUCs in the absence of LIF/2-MCE as compared to ESCs cultured on MEFs. Semi-quantitative RT-PCR indicated that Nanog expression was higher when ESCs were grown on RUCs in the absence of LIF and 2-MCE as compared to MEFs in the same treatment conditions. Bisulfite-mediated methylation analysis of the Nanog proximal promoter suggested that the maintenance of Nanog gene expression found in ESCs grown on RUCs after culture for 96 hours in the absence of LIF/2-MCE may be due to prevention of methylation of the CpG dinucleotides in the Nanog proximal promoter as compared to ESCs grown on MEFs. Thus, RUCs may release factors into the medium that maintain the pluripotent state of mouse ESCs in the absence of LIF and 2-MCE.

Des changements de méthylation de l'ADN peuvent affecter l'expression des gènes et pour certains être transmis au travers des générations. De telles " épimutations " qui concernent des groupes de cytosines à proximité ou dans les gènes sont donc une source potentielle de variation phénotypique héritable en absence de changements de la séquence de l'ADN. Chez les plantes la méthylation de l'ADN est cependant principalement observée au niveau des séquences répétées. Il reste à déterminer dans quelle mesure les changements de méthylation au niveau de ce type de séquences peuvent être héritées et affecter les phénotypes. Afin de répondre à ces questions, plus de 500 épiRIL (epigenetic Recombinant Inbred Lines) quasi-isogéniques a été générée chez Arabidopsis thaliana. Cette population a été obtenue par le croisement d'un parent sauvage et d'un parent mutant pour le gène DDM1 présentant une très forte réduction du taux de méthylation de l'ADN. Après un rétrocroisement de la F1 avec une plante sauvage, les individus sauvages pour le gène DDM1 ont été sélectionnés et propagées sur 6 générations par autofécondation. Nous avons montré par l'analyse du méthylome de plus de 100 épiRIL que l'hypométhylation induite par ddm1 présente selon les séquences affectées différents degrés de transmission au travers des générations. La réversion de l'hypométhylation concerne des régions associées à une abondance élevée en sRNA de 24 nt. Nous avons utilisé l'hypométhylation stablement transmise dans les épiRIL induite par ddm1 afin de détecter des QTL (Quantitative Trait Loci) affectant le temps de floraison et la longueur de la racine primaire, deux caractères pour lesquels les variations observées dans les épiRIL présentent une héritabilité importante. En dernier lieu, nous avons recherché par différentes approches les variations causales de ces QTL.

Résumé : L’obésité est un enjeu de société de première importance; elle est un facteur de risque de plusieurs maladies et engendre d’importantes dépenses en santé. Outre l’alimentation, la sédentarité et les prédispositions génétiques, il semble que l’environnement fœtal soit un facteur déterminant dans le développement de l’obésité. En effet, il a été démontré que les nouveau-nés exposés à un environnement intra-utérin défavorable ont un risque accru de développer, à l’adolescence et à l’âge adulte, l’obésité ainsi que les désordres métaboliques qui y sont associés. Le diabète gestationnel (DG) est l’une des complications de santé maternelle les plus fréquentes et est associé à un risque accru à long terme pour la santé métabolique de l’enfant. Malgré les nombreuses données probantes épidémiologiques concernant le phénomène de la programmation fœtale associée au DG, les mécanismes moléculaires impliqués ont été très peu étudiés. Il est cependant de plus en plus évident que l’épigénétique soit l’un de ces mécanismes. Cette thèse a pour objectif d’identifier les changements de méthylation de l’ADN, la modification épigénétique la plus stable et la plus connue, chez les nouveau-nés exposés in utero au DG. Dans un premier temps, la méthylation de l’ADN de 44 échantillons de placenta et de sang de cordon a été analysée à l’échelle du génome. Cette approche a permis de démontrer que les gènes épigénétiquement modifiés suite à une exposition au DG sont majoritairement retrouvés dans les voies biologiques associées aux maladies métaboliques. Des analyses dans une cohorte indépendante (n=80) ont confirmé l’effet de la glycémie maternelle sur la méthylation de l’ADN des gènes BRD2, LRP1B et CACNA1D impliqués dans la régulation du métabolisme des lipides et du glucose et du système rénine-angiotensine respectivement. Dans un second temps, l’approche par gènes candidats a démontré que l’exposition au DG est associée à la méthylation de l’ADN de gènes du métabolisme des lipides (LPL et ABCA1) du placenta. L’analyse de la méthylation de la LEP et de l’ADIPOQ dans le sang et les tissus adipeux de sujets sévèrement obèses a permis d’identifier des sites de méthylation pouvant potentiellement être utilisés dans le sang comme marqueur de susceptibilité à l’obésité. L’ensemble des résultats de cette thèse démontrent que le DG modifie le profil épigénétique de gènes impliqués dans les voies biologiques des maladies métaboliques (métabolisme énergétique et des lipides) et supportent l’importance de la méthylation de l’ADN dans la programmation de la santé métabolique du nouveau-né ayant été exposé in utero au DG. / Abstract : Obesity has reached epidemic proportions worldwide in both adult and childhood populations and is now recognized as a major public health issue. Obesity is associated with higher incidence of cardiometabolic complications including type 2 diabetes (T2D), dyslipidemia and hypertension as well as with increased health care costs. The fetal environment now appears, with genetics and the environment, as one cause of the obesity epidemic. Indeed, according to the fetal programming hypothesis, newborns exposed to a detrimental fetal environment are more susceptible to develop obesity, T2D and other related chronic disorders when they become teenagers or adults. Many studies have associated gestational diabetes mellitus (GDM) exposure with these long-term metabolic health risks for the newborn. Although, numerous studies show epidemiological evidence to support the fetal programming hypothesis, only a few studies have been undertaken to understand the underlying molecular mechanisms. However, several studies now suggest that epigenetics may be involved. The objective of this thesis is to study changes in DNA methylation, the more stable and studied epigenetic system, in newborns that have been exposed to GDM in utero. First, a genome-wide DNA methylation analysis (BeadChip) was performed in a sample set of 44 placenta and cord blood samples to identify genes and metabolic pathways dysregulated by GDM. This approach showed that genes epigenetically affected by GDM are predominantly involved in metabolic diseases. The associations between maternal glycemia and DNA methylation levels were confirmed, in an independent birth cohort, for BRD2, LRP1B and CACNA1D gene loci involved in the regulation of lipid and glucose metabolism and the renin-angiotensin system respectively. Then, using a candidate gene approach we reported that DNA methylation levels at gene loci involved in lipid metabolism (LPL and ABCA1) are modified in the placenta following exposure to GDM. Furthermore, analyses of LEP and ADIPOQ DNA methylation levels in blood and adipose tissues of severely obese men and women allowed the identification of CpG sites that might be used in blood as a marker of obesity susceptibility. Altogether the results of this thesis show that GDM affects the epigenetic signature of genes involved in metabolic disease pathways (energy and lipid metabolism) and support the role of DNA methylation in metabolic health programming of the newborn exposed to GDM.

Les marqueurs épigénétiques, en particulier la méthylation de l’ADN des gènes soumis à empreinte parentale, sont sensibles aux changements environnementaux. Les techniques de l’aide médicalisée à la procréation (AMP) nécessitant la manipulation des gamètes et des embryons in vitro et dans la plupart des cas la stimulation hormonale de l’ovulation des patientes, peuvent interférer avec la reprogrammation et/ou le maintien de la méthylation des gènes soumis à empreinte. Afin d’évaluer ce risque nous avons analysé le profil de méthylation de KvDMR1, qui régule l’expression de KCNQ1OT1, dans des ovocytes humains mûris in vivo ou in vitro, provenant de patientes stimulées ou non. Nos résultats montrent que la mise en place de la méthylation au niveau de KvDMR1 se poursuit au cours de la maturation de l’ovocyte après reprise de la méiose, in vivo et in vitro et que la superovulation des patientes en AMP génère des ovocytes épigénétiquement immatures. Par ailleurs, l’étude de la méthylation de KvDMR1 et de H19 DMR (qui régule l’expression d’Igf2 et H19) dans des embryons issus d’ICSI, évolutifs ou présentant un défaut de développement, n’établit pas de lien entre les dérégulations de l’empreinte et l’arrêt du développement embryonnaire au stade blastocyste. / Epigenetic modifications, particularly DNA methylation of imprinted genes are sensible to environment. Techniques of assisted reproduction require in vitro manipulation of gamete and embryos and currently superovulation of patients. These technologies may interfere with eprogramming and maintenance of methylation at imprinted genes. To evaluate such a risk, we have determined the methylation profile of KvDMR1, the region that regulates KCNQ1OT1 imprinted gene, in human oocytes retrieved from stimulated or unstimulated cycles, at different phases of their maturation in vivo or in vitro. Our results show that the timing of establishment of the methylation profile of KvDMR1 covers the maturation phase of 199 oocyte growth, in vivo and in vitro, and that hyperstimulation likely recruits young follicles epigenetically immature. Analysis of the methylation profile of KvDMR1 and H19DMR (DMR of IGF2/H19) in ICSI embryos suggests that imprinting disorders are not responsible of embryo developmental failure prior the blastocyst stage